Patent Expiry
5 articles on Patent Expiry, written by Shotlee and medically reviewed for clinical accuracy.
Emcure Halves Poviztra Semaglutide Price After Novo Nordisk Patent Expiry
Emcure Pharmaceuticals has halved the price of its semaglutide-based weight loss drug Poviztra after the expiry of Novo Nordisk's patent, making GLP-1 therapy more accessible. Originally developed for diabetes, semaglutide mimics hormones to control appetite and blood sugar, delivering unmatched weight loss results. Check the new rates and learn what this means for patients seeking effective metabolic treatments.
4 min read
Safety Signals Matter as Semaglutide Scales in India
Semaglutide's patent expiry in India has flooded the market with affordable generics, dropping prices from over ₹10,000 to as low as ₹1,300 per month. While this opens access for millions with Type 2 diabetes and obesity, experts warn of safety risks from misuse without proper guidance. Discover the implications for patients and the growing market.
5 min read
Low-Cost Semaglutide Generics Coming to India as Patent Expires
India's Semaglutide patent expires March 20, opening doors for low-cost generics from pharma giants like Zydus, Torrent, Sun Pharma, and Dr. Reddy's. With over 23% of women and 22% of men overweight per NFHS-5, and 45 crore adults projected obese by 2050, affordable options could reshape the fight against obesity and diabetes. Discover the price revolution and challenges ahead.
5 min read
Semaglutide Generics Set for One-Fourth Price After Patent Expiry
Semaglutide prices in India are poised for a dramatic drop to one-fourth of current levels following patent expiry on March 20. Generics from seven companies like Sun Pharma and Zydus Lifesciences will make Ozempic and Wegovy alternatives more accessible for diabetes and obesity management. Experts highlight improved adherence but warn of misuse risks.
5 min read
Ozempic-Like Drugs in India May Drop 50% in Price from March 2026
Semaglutide-based weight-loss drugs like Ozempic and Wegovy are set for a price revolution in India, with generics launching after patent expiry on March 20, 2026, potentially halving costs. Domestic giants like Sun Pharmaceutical and Dr. Reddy's are gearing up to make these GLP-1 therapies more affordable amid rising obesity rates. This shift could transform access to effective treatments for diabetes and weight management.
5 min read